Title : Novel Agents in Chronic Lymphocytic Leukemia: New Combination Therapies and Strategies to Overcome Resistance.

Pub. Date : 2021 Mar 16

PMID : 33809580






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The approval of Bruton"s tyrosine kinase (BTK) inhibitors such as ibrutinib and acalabrutinib and the Bcl-2 inhibitor venetoclax have revolutionized the treatment of chronic lymphocytic leukemia (CLL). ibrutinib Bruton tyrosine kinase Homo sapiens
2 The approval of Bruton"s tyrosine kinase (BTK) inhibitors such as ibrutinib and acalabrutinib and the Bcl-2 inhibitor venetoclax have revolutionized the treatment of chronic lymphocytic leukemia (CLL). ibrutinib Bruton tyrosine kinase Homo sapiens